Login to view
Course Activities.
|
Title: |
Activity/Course #: |
Cost: |
Release/Start Date: |
Expiration Date: |
Topics: |
Target Audience: |
Medium/Method: |
Estimated Time To Complete CME Activity: |
Hardware/Software Requirements: |
Credits: |
|
This program was captured live at the NACE Emerging Challenges in Primary Care: Update 2007 series and features Dr. Fernando Ovalle. Dr. Ovalle, is the Associate Professor of Medicine, Director of the Clinical Research Unit, the Fellowship Training Program, Division of Endocrinology and Diabetes & Metabolism at the University of Alabama at Birmingham School of Medicine. Learning Objective(s): After completing this program participants should be able to:
- identify when, how, and which insulin to start when managing patients with Type 2 Diabetes
- identify and understand available options for treating post-prandial hyperglycemia as well as the role incretin hormones play in the management of diabetes
This webcast was recorded live and is being used with the permission of the presenter. |
|
|
National Association for Continuing Education
|
| The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Association for Continuing Education designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
Fernando Ovalle, MD made the following disclosures:
Grants funded—GSK, Novo Nordisk, Pfizer, Sanofi-Aventis, Amylin, Eli Lilly, and AstraZeneca.
Speaker's Bureau—GSK, Amgen, Eli Lilly, Novo Nordisk, Merck, and Pfizer.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Harvey Parker, PhD, Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose. |
|
No commercial support was provided for this enduring activity. The following companies provided commercial support for the live CME activity entitled Emerging Challenges in Primary Care: Update 2007 held in Birmingham, AL on March 31, 2007 during which this presentation was held:Amylin, AstraZeneca, Boehringer Ingelheim, Collagenex, Merck, NovoNordisk, sanofi-aventis, Takeda Pharmaceuticals of North America, Wyeth. |
|
